Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with...
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
About this item
Full title
Author / Creator
Rosano, Giuseppe , Ponikowski, Piotr , Vitale, Cristiana , Anker, Stefan D. , Butler, Javed , Fabien, Vincent , Filippatos, Gerasimos , Kirwan, Bridget-Anne , Macdougall, Iain C. , Metra, Marco , Ruschitzka, Frank , Kumpeson, Vasuki , Goehring, Udo-Michael , van der Meer, Peter , Jankowska, Ewa A. and the AFFIRM-AHF investigators
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure (HF) hospitalization and improved quality of life (QoL) vs placebo in patients stabilized following an acute HF (AHF) episode, with no effect on cardiovascular (CV) death. Diabetes and iron deficiency frequently acco...
Alternative Titles
Full title
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_351511ae7e4e47f08ac3be599fe42e1f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_351511ae7e4e47f08ac3be599fe42e1f
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-023-01943-z
